Bristol-Myers Squibb and Gilead Sciences are major biopharma firms, with Gilead Sciences recently employing Lena Moran-Adams.
1 report, 1 independent
Updated Jul 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bristol-Myers Squibb and Gilead Sciences are major biopharma firms, with Gilead Sciences recently employing Lena Moran-Adams.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
Related events
- Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
- Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.
- Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.